SURVEY ON USE AND PERCEPTION OF AMIKACIN FOR TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE IN THE UK

被引：0
|
作者：
Obradovic, M. [1 ]
Van der Laan, R. [1 ]
Hale, J. [2 ]
Gerden, E. [2 ]
Musson, L. [2 ]
机构：
[1] Insmed GE, Frankfurt, Germany
[2] Sionis, Portsmouth, Huijbergen, England
来源：
THORAX | 2021年 / 76卷
关键词：
D O I：
10.1136/thorax-2020-BTSabstracts.308
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P163
引用
收藏
页码：A177 / A178
页数：2
相关论文
共 50 条
  • [1] Treatment for Mycobacterium avium complex lung disease
    Pan, Sheng-Wei
    Shu, Chin-Chung
    Feng, Jia-Yih
    Su, Wei-Juin
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 : S67 - S75
  • [2] The treatment outcomes of cavitary Mycobacterium avium complex pulmonary disease according to the use of amikacin or streptomycin
    Kim, Seong Min
    Shim, Tae Sun
    Jo, Kyung-Wook
    [J]. RESPIROLOGY, 2023, 28 : 204 - 204
  • [3] Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use
    Kim, Seong Min
    Chong, Yong Pil
    Lee, Hyun Joo
    Shim, Tae Sun
    Jo, Kyung-Wook
    [J]. MICROBIOLOGY SPECTRUM, 2023, 11 (03):
  • [4] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Matt Shirley
    [J]. Drugs, 2019, 79 : 555 - 562
  • [5] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Shirley, Matt
    [J]. DRUGS, 2019, 79 (05) : 555 - 562
  • [6] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Sheridan M. Hoy
    [J]. Clinical Drug Investigation, 2021, 41 : 405 - 412
  • [7] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Hoy, Sheridan M.
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 405 - 412
  • [8] Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Matt Shirley
    [J]. Drugs, 2019, 79 : 791 - 791
  • [9] Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Sheridan M. Hoy
    [J]. Clinical Drug Investigation, 2021, 41 : 591 - 591
  • [10] Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT)
    Griffith, David E.
    Eagle, Gina
    Thomson, Rachel
    Aksamit, Timothy R.
    Hasegawa, Naoki
    Morimoto, Kozo
    Addrizzo-Harris, Doreen J.
    O'Donnell, Anne E.
    Marras, Theodore K.
    Flume, Patrick A.
    Loebinger, Michael R.
    Morgan, Lucy
    Codecasa, Luigi R.
    Hill, Adam T.
    Ruoss, Stephen J.
    Yim, Jae-Joon
    Ringshausen, Felix C.
    Field, Stephen K.
    Philley, Julie V.
    Wallace, Richard J., Jr.
    van Ingen, Jakko
    Coulter, Chris
    Nezamis, James
    Winthrop, Kevin L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (12) : 1559 - 1569
12345